BAX
Baxter International Inc operates in the healthcare industry. It provides renal and hospital products such as infusion systems and systems, parenteral nutrition therapies, and biosurgery products.
Baxter International Inc. (BAX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Growth (C-). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | B (3.2) | C- (1.9) | B- (3.1) | B+ (3.7) | C- (2.1) | C+ (2.8) |
| 2026-11-09 | B (3.2) | C- (1.9) | B- (3.1) | B (3.3) | C- (2.1) | C+ (2.7) |
| 2026-11-02 | B (3.2) | C- (1.9) | B- (3.1) | B- (3.0) | C- (2.1) | C+ (2.7) |
| 2026-11-01 | B (3.2) | C- (2.1) | B- (3.1) | B (3.2) | B+ (3.5) | B- (3.0) |
| 2026-10-30 | B (3.2) | C- (2.1) | B- (3.1) | B (3.2) | B (3.4) | B- (3.0) |